论文部分内容阅读
目的 :探讨多巴胺受体 ( DRD4 )基因第一外显子中 Not 酶切位点甲基化与急性非淋巴细胞白血病( AML)的关系。方法 :应用 Southern印记杂交及 DNA序列分析技术对 AML 患者骨髓标本进行分析。结果 :在 2 7例白血病患者骨髓标本中 16例 DRD4基因甲基化 ( 5 9% ) ,其中初治化疗敏感患者 DRD4基因甲基化发生率为5 0 % ( 9/18) ,复发及难治患者甲基化发生率为 78% ( 7/9) ,而 9例正常人骨髓标本 DRD4基因均无甲基化。结论 :DRD4基因甲基化在白血病患者发生率明显高于正常人 ( P<0 .0 5 ) ,而在复发及难治患者其发生率略高于初治化疗敏感患者 ,DRD4基因甲基化可能与白血病的发生、发展有一定关系
Objective: To investigate the relationship between the methylation of the Not-excision site in the first exon of dopamine receptor (DRD4) gene and the relationship between acute non-lymphoblastic leukemia (AML). METHODS: Southern blot hybridization and DNA sequence analysis techniques were used to analyze bone marrow samples of AML patients. RESULTS: The methylation of DRD4 gene was found in 16 cases (27%) of bone marrow samples from 27 patients with leukemia. The incidence of methylation of DRD4 gene in sensitive patients was 50% (9/18). The incidence of methylation in the treated patients was 78% (7/9), and 9 cases of normal people had no methylation of the DRD4 gene in the bone marrow samples. Conclusion: The incidence of methylation of DRD4 in leukemia patients was significantly higher than that in normal subjects (P 0.05), but the incidence of DRD4 gene methylation was higher in relapsed and refractory patients than in newly treated chemotherapy-sensitive patients. May have a relationship with the occurrence and development of leukemia